ArticleFrontiers in cellular and infection microbiology2026
Bta-miR-146b promotes infectious bovine rhinotracheitis virus replication and inhibits type I interferon expression via targeting IRAK1.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infectious bovine rhinotracheitis virus (IBRV) is a primary pathogen causing bovine respiratory disease syndrome. This virus can cause rhinotracheitis and vaginitis in cattle, resulting in high mortality and posing a serious threat to bovine production. MicroRNAs (miRNAs), a class of regulatory non-coding small RNAs, can modulate viral replication by influencing host immune responses. However, reports on the association between host miRNAs and IBRV infection are limited. Methods: In this study, we screened differentially expressed miRNAs in MDBK cells after IBRV infection and determined that the expression of bta-miR-146b was significantly increased. We investigated the effects of bta-miR-146b on IBRV replication and its underlying molecular mechanisms using molecular biological techniques such as luciferase activity assays, Western Blot, and qRT-PCR, together with bioinformatics approaches. Results: We found that bta-miR-146b expression was up-regulated in IBRV-infected MDBK cells. Furthermore, transfection with bta-miR-146b mimics promoted IBRV replication in MDBK cells, whereas transfection with bta-miR-146b inhibitors inhibited IBRV replication, indicating that bta-miR-146b is a pro-infection factor. Additional studies showed that bta-miR-146b mimics inhibited type I interferon expression in MDBK cells, whereas its inhibitors enhanced it. Moreover, we identified IRAK1 as a direct target of bta-miR-146b and found that silencing IRAK1 expression rescued the effects of bta-miR-146b on viral replication and type I interferon expression. Conclusion: These results suggest that bta-miR-146b regulates type I interferon expression and IBRV replication in MDBK cells by targeting IRAK1, and plays a key role in IBRV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.